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Abstract
Background: Concurrent chemoradiation is the standard treatment for patients with advanced head and neck
squamous cell carcinoma (HNSCC).
The present study was carried out to assess the feasibility and efficacy of low-dose gemcitabine as a radiosensitizer
when used during radical therapeutic management of patients with locally advanced HNSCC.
Patients and methods: Fifty-two patients with locally advanced HNSCC (stage III, 50%; stage IVa, 50%) were
enrolled during the period from July 2008 to December 2010. All received a course of radiotherapy (70 Gy over 7
weeks) concurrent with weekly infusions of gemcitabine at 50 mg/m
2.
Results: All patients were available for toxicity and response. Severe mucositis (grade 3-4) was observed in 76% of
patients. Severe hematological toxicity was uncommon. Xerostomia was the most common late toxicity in 34
patients (65.4%). The rate of complete and partial response rate was 67.3% and 21.1%, respectively, with an overall
response rate of 88.45%. Two years progression-free survival and disease-free survival were 46% and 38.46%,
respectively.
Conclusion: Using low-dose gemcitabine concurrent with radiotherapy maintains high response rate with low
systemic toxicity, in spite of severe mucositis in a high percentage of patients.
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Introduction
Head and neck malignancies constitute 5% of all cancers
worldwide [1]. The majority of these patients diagnosed
with locally advanced disease and with lymph node
involvement in up to 30-50% [2].
Locoregionally advanced head and neck carcinoma is
generally treated by a combination of chemoradiother-
apy, with or without surgery [3].
Because of the high incidence of advanced disease at
presentation and local failure rates (50-60%), the man-
agement of head and neck carcinoma is a challenging
proposition [4].
Radiation has been the standard treatment for locally
advanced cancer of the head and neck. These patients,
when treated with exclusive radiation, have a 5-year sur-
vival rate of less than 25%, and most treatment failures
occur locally or regionally within the irradiated fields.
Chemotherapy has been combined with radiation in an
attempt to improve the outcome, the most promising
approach being the administration of chemotherapy
concurrent with radiation [4,5].
Concurrent chemotherapy and radiotherapy are widely
adopted as the standard of care for locoregionally
advanced squamous cell carcinoma of the head and
neck after the publication of a large meta-analysis,
including individual data on 10,741 patients in 63 ran-
domized trials [6].
Many trials of concurrent chemoradiation have used
cisplatin in combination with 5-fluorouracil; however,
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ter than cisplatin alone [7].
It has been postulated that radiosensitization with
gemcitabine is due to the depletion of deoxyadenosine
triphosphate (dATP) through inhibition of ribonucleo-
tide reductase by the present DNA damage caused by
radiation that cannot be repaired, and this leads to an
increase in cell death (Lawrence, 1996) [8].
In 1997, Eisbruch et al. reported the preliminary
results of a phase I study evaluating low-dose gemcita-
bine concurrently with standard radiation. They found
high tumor control at a dose of 300 mg/m
2 per week,
although excessive mucosal toxicity led them to reduce
the dose. Another preliminary study with 200 mg/m2
per week was performed, and encouraging response rate
was observed (75% complete response), where all the
patients developed grade III mucositis, and 1 patient
died during treatment. Because of this, the study was
terminated [9].
Patients and methods
Nature of the study
It is a prospective phase II non-randomized clinical trial
including 52 patients with locally advanced, non-meta-
static squamous cell carcinoma of the head and neck.
Patients were recruited from the clinical oncology out-
patient clinic at Sohag University Hospital. The study
was approved by the local ethical committee of the uni-
versity. All patients were given the informed consent to
read, and only those who agreed to sign the consent
were included.
Eligibility criteria
￿ Patients with histopathologically proven squamous cell
carcinoma of the head and neck.
￿ Stage III, IV (non-metastatic disease).
￿ Age more than 18 and less than 70 years old.
￿ WHO performance status 0, 1, or 2.
￿ Adequate hematological, renal, and hepatic
functions.
￿ No prior chemotherapy or radiotherapy.
￿ All patients signed an informed consent.
Pretreatment evaluation
￿ Clinical examination
* Including history, complete physical examination,
and head and neck examination, with attention to cervi-
cal lymphadenopathy and its site, size, consistency, bila-
terality, and whether fixed or mobile.
* Dental evaluation with management of dental pro-
blems and oral hygiene caring prior to starting
radiotherapy.
￿ Laboratory
* Including complete blood count, renal and liver
function tests should be done every 2 weeks and then
every month during the first year.
￿ Endoscopic evaluation
Rigid and fibro-optic panendoscopies were performed,
with mapping of the extension of the lesion for proper
staging. Also, careful inspection of all mucosal lining to
exclude other primary or precancerous lesions and
biopsy was taken.
￿ Radiological
* Including CT scan for the primary site, chest x-ray,
abdominal ultrasonography, and bone scan, if indicated.
Treatment protocol
Patients received a course of radiotherapy, once daily, 2
Gray per fraction, for 5 days per week. The total dose to
the macroscopic tumor and to potential sites of spread
was 70 Gray, to be delivered over 7 weeks.
Concurrent chemotherapy with a course of gemcita-
bine was administered intravenously over 30 minutes
once a week, 1-2 hours before radiotherapy, for 7 conse-
cutive weeks, at a dose of 50 mg/m
2.
Evaluation during and post-treatment
All patients were clinically evaluated twice a week dur-
ing treatment.
￿ Toxicity
Toxicity was evaluated weekly according to World
Health Organization (WHO) scoring system. Any grade
4 toxicity warranted a 1-week delay in the administra-
tion of both chemotherapy and radiotherapy.
￿ Response criteria
Assessment of the response was performed 4-6 weeks
after the end of treatment according to WHO criteria.
Tumor response was evaluated by physical examina-
tion, head and neck CT, and endoscopy with biopsy of
the tumor bed.
Complete response (CR) was defined as the disappear-
ance of all evidence of disease by physical examination,
CT, and direct endoscopy.
Partial response (PR) was defined as a reduction by
50% of the product of the largest perpendicular dia-
meters of measurable disease, with no progression at
other sites of disease and no appearance of new lesions.
Tumor progression was considered if there was an
increase by 25% in the product of the longest perpendi-
cular diameters of tumor lesions or the appearance of
new ones.
Statistical analysis
Data analysis (mean, median, survival analysis, and
graphs) was performed by Intercooled Stata version
9.2.
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From July 2008 to December 2010, 52 patients from the
clinical oncology department at Sohag University Hospi-
tal were enrolled in this trial; males were 36, and
females were 16, with a median age of 54 years ranging
from 25 to 70 years.
Table (1) shows baseline characteristics of study sub-
jects. Baseline hemoglobin level ranged from 9.9 gm/dl
to 15.8 gm/dl, with a median of 12 gm/dl.
According to ECOG classification of performance sta-
tus, nearly all patients ranked in class 1 and 2, and just
2 patients ranked in class 0.
Overall treatment time
The median overall time was 8 weeks ranging from 7 to
10 weeks. Eight patients had interruption due to severe
toxicity, mainly mucositis.
Toxicity
All 52 patients were available for toxicity; acute toxici-
ties were common but manageable (Table 2), and muco-
sitis and dysphagia were the most common acute
toxicities. The incidence of grade 3-4 mucositis was
observed in 40 patients (76.92%), grade 2 dysphagia was
noticed in 22 patients (42.31%), and grade 3 dysphagia
was noticed in 12 patients (23.08%).
Hematological toxicity was uncommon, with grade 3
neutropenia being noticed in 2 patients in week 5 dur-
ing the course of treatment.
Late toxicity was observed as grade 2 xerostomia in 34
patients (65.4%). No objective evaluation of swallowing
function was performed.
Response to treatment
All 52 patients were available for response. The overall
response rate was observed in 88.45% of patients.
Thirty-five patients (67.30%) achieved a complete
response, 11 patients (21.15%) showed partial response,
Table 1 Baseline characteristics of study subjects
Characteristics No. %
Sex
*female 16 30.77
*male 36 69.23
Age
* < 50 16 30.77
* ≥ 50 36 69.23
*mean (SD) 53.73 (11.35)
*median (range) 54 (25-70)
Performance status
*0 2 3.85
*1 24 46.15
*2 26 50
Baseline Hemoglobin
*mean (SD) 12.39 (1.89)
*median (range) 12 (9.9-15.8)
Site of primary tumor
* nasopharynx 4 7.69
* hypopharynx 8 15.38
* larynx 26 50
* maxilla 2 3.85
* paranasal sinus 2 3.85
* tongue 10 19.23
T stage
*T1 4 7.69
*T2 12 23.08
*T3 20 38.46
*T4 16 30.77
N stage
* N0 10 19.23
* N1 10 19.23
* N2 32 61.54
Grade
*I 4 7.7
*II 34 65.4
*III 14 26.9
Stage
*III 26 50
*IVa 26 50
Table 2 acute toxicities
Acute toxicities-grade No. of patients %
Vomiting
0 10 19.23
12 6 5 0
2 14 26.92
3 2 3.85
Dysphagia
0 4 7.69
1 14 26.92
2 22 42.31
3 12 23.08
Mucositis
0 0 0.0
1 2 3.85
2 10 19.23
3 24 46.15
4 16 30.77
Skin
0 4 7.69
1 32 61.54
2 14 26.92
3 2 3.85
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patients had disease progression.
The median duration of response was 21 months
range (4-30).
There was no correlation of response with tumor
grade, nodal status, or primary site.
Outcome
The median follow-up time was 24 months (4-30).
Five patients of 17 patients who did not achieve com-
plete remission underwent salvage surgery, and the
other 12 patients received palliative chemotherapy.
Three patients of the 35 patients, who had achieved
complete remission, relapsed after 1 year of follow-up, 1
patient underwent salvage surgery, and 2 patients
refused surgery and received chemotherapy.
T h em e d i a nt i m eo fd i s e a s ep r o g r e s s i o nw a s2 1 . 5
months (4-30), with 2 years progression-free survival
(PFS) of 46% (Figure 1), and the median disease-free
survival (DFS) was 20 months (0-30), with 2 years DFS
of 38.46 (Figure 2).
Discussion
Although concurrent chemoradiation has become the
standard of care for advanced and/or unresectable head
and neck carcinoma patients, the best drug and schedule
for chemoradiotherapy remains to be undermined.
This trial was designed to test the efficacy and toxicity
of a regimen of weekly gemcitabine, concurrent with
radiotherapy in patients with advanced HNSCC. Thirty-
six (68.5%) patients had T3 and T4 nodes, and 32
(61.5%) patients had N2 nodes. Despite these unfavor-
able patients’ characteristics, this regimen showed an
encouraging tumor response rate and acceptable survival
results.
In the present study, we achieved an overall response
rate of 88.45% (67.30% complete response, 21.15% par-
tial response). This result is in agreement with the result
reported by Aguilar et al., 2004, who achieved an overall
r e s p o n s er a t eo f8 8 % .I ti sa l s oc o m p a r a b l ew i t ht h e
result reported by Eisbrush et al., 2001, who achieved
66% complete response rate [10,9].
We observed a significant rate of grade 3-4 mucositis
(76%). This was in agreement with the result of Aguilar
et al., 2004, in which 74% of grade 3-4 mucositis was
reported, and also with Shaharyar et al., 2006, who
reported 77% of grade 3-4 mucositis in their study
[10,11].
In our study, the hematological toxicity was mild,
and grade 3 neutropenia was observed in 2 patients;
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Figure 1 progression- free survival curve.
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bruch et al., 2001, and Aguilar et al., 2004 [9,10].
In our study, the median time to disease progression
was 21.5 months, with 2 years PFS of 46%, and the med-
ian disease-free survival was 20 months, with 2 years
DFS of 38.46%. Our result is lower than that of Chau-
han et al., 2008, and this may be because the median
follow-up time is longer in our study compared with
their study, which was 11 months [12].
Conclusion
The concurrent use of radiotherapy and low-dose gem-
citabine demonstrated an encouraging response rate as
compared to other chemoradiation trials.
Gemcitabine at relatively low doses is a potent radio-
sensitizer in HNSCC patients, but it produces a high
incidence of mucositis. Further studies are needed to
optimize the administration of gemcitabine with
radiation.
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